Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Subcutaneous abatacept in CTLA4 insufficiency or LRBA deficiency
2019-000972-40Phase 2Completed
- Sponsor
- Universitätsklinikum Freiburg
- Start
- Feb 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of abatacept in CTLA4 deficiency, LRBA deficiency (LRBA) and common variable immunodeficiency (CVID), sponsored by Universitätsklinikum Freiburg. Primary endpoint: Failed infection control episodes over one year. Started Feb 2020; status: completed.
02
Drugs
abatacept
03
Conditions
CTLA4 deficiencyLRBA deficiency (LRBA)common variable immunodeficiency (CVID)
Beyond the preview
Go deeper on 2019-000972-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000972-40.